Locally Advanced Adenoid Cystic Carcinoma of the Breast—A Case Report with a Review of the Literature
Abstract
:1. Introduction
2. Materials and Methods
3. Case Report
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
Abbreviations
ABPAS | Alcian Blue periodic acid-Schiff |
ACC | adenoid cystic carcinoma |
AMACAR | alpha-methylacyl-CoA racemase |
BC | breast cancer |
BLIA | basal-like immune-activated |
BLIS | basal-like immune-suppressed |
CAP | cyclophosphamide + doxorubicin + cisplatin schedule |
CEA | carcinoembryonic antigen |
CK | cytokeratin |
CR | complete response |
CT | computed tomography |
CTH | chemotherapy |
DFS | disease-free survival |
DXL | docetaxel |
DXR | doxorubicin |
EBUS | endobronchial ultrasound |
ER | estrogen receptor |
FAC | 5-fluorouracil + doxorubicin + cyclophosphamide schedule |
GATA-3 | GATA binding protein 3 |
HE | hematoxylin and eosin |
HER2 | human epidermal growth factor receptor 2 |
LAR | luminal androgen receptor |
MES | mesenchymal |
mo | month |
ND | not done |
NVB | vinorelbine |
OS | overall survival |
PAX-8 | paired-box gene 8 |
PD | progressive disease |
PET-CT | positron emission tomography-computed tomography |
PR | progesterone receptor |
RTH | radiation therapy |
SD | stable disease |
SMA | smooth muscle actin |
SLNB | sentinel node biopsy |
TKI | tyrosine kinase inhibitor |
References
- Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021, 71, 209–249. [Google Scholar] [CrossRef]
- Shaath, H.; Elango, R.; Alajez, N.M. Molecular Classification of Breast Cancer Utilizing Long Non-Coding RNA (LncRNA) Transcriptomes Identifies Novel Diagnostic LncRNA Panel for Triple-Negative Breast Cancer. Cancers 2021, 13, 5350. [Google Scholar] [CrossRef]
- Ramamoorthy, P.; Dandawate, P.; Jensen, R.A.; Anant, S. Celastrol and Triptolide Suppress Stemness in Triple Negative Breast Cancer: Notch as a Therapeutic Target for Stem Cells. Biomedicines 2021, 9, 482. [Google Scholar] [CrossRef]
- Yao, H.; He, G.; Yan, S.; Chen, C.; Song, L.; Rosol, T.J.; Deng, X. Triple-Negative Breast Cancer: Is There a Treatment on the Horizon? Oncotarget 2017, 8, 1913–1924. [Google Scholar] [CrossRef]
- Badowska-Kozakiewicz, A.M.; Budzik, M.P. Immunohistochemical Characteristics of Basal-like Breast Cancer. Contemp. Oncol. (Pozn) 2016, 20, 436–443. [Google Scholar] [CrossRef]
- Burstein, M.D.; Tsimelzon, A.; Poage, G.M.; Covington, K.R.; Contreras, A.; Fuqua, S.A.W.; Savage, M.I.; Osborne, C.K.; Hilsenbeck, S.G.; Chang, J.C.; et al. Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer. Clin. Cancer Res. 2015, 21, 1688–1698. [Google Scholar] [CrossRef]
- Arpino, G.; Clark, G.M.; Mohsin, S.; Bardou, V.J.; Elledge, R.M. Adenoid Cystic Carcinoma of the Breast: Molecular Markers, Treatment, and Clinical Outcome. Cancer 2002, 94, 2119–2127. [Google Scholar] [CrossRef]
- Marco, V.; Garcia, F.; Rubio, I.T.; Soler, T.; Ferrazza, L.; Roig, I.; Mendez, I.; Andreu, X.; Minquez, C.G.; Tresserra, F. Adenoid Cystic Carcinoma and Basaloid Carcinoma of the Breast: A Clinicopathological Study. Rev. Esp. Patol. 2021, 54, 242–249. [Google Scholar] [CrossRef] [PubMed]
- Spiro, R.H.; Huvos, A.G. Stage Means More than Grade in Adenoid Cystic Carcinoma. Am. J. Surg. 1992, 164, 623–628. [Google Scholar] [CrossRef] [PubMed]
- Khan, A.J.; DiGiovanna, M.P.; Ross, D.A.; Sasaki, C.T.; Carter, D.; Son, Y.H.; Haffty, B.G. Adenoid Cystic Carcinoma: A Retrospective Clinical Review. Int. J. Cancer 2001, 96, 149–158. [Google Scholar] [CrossRef] [PubMed]
- Ahn, S.K.; Kim, K.; Choi, I.J.; Lee, J.M. Adenoid Cystic Carcinoma of the Prostate Gland: Pathological Review with a Case Report. Yonsei Med. J. 1991, 32, 74–78. [Google Scholar] [CrossRef] [PubMed]
- Boggio, R. Adenoid Cystic Carcinoma of Scalp. Arch. Dermatol. 1975, 111, 793. [Google Scholar] [CrossRef] [PubMed]
- Rosen, P.P. Adenoid cystic carcinoma of the breast: A morphologically heterogenous neoplasm. Pathol. Annu. 1989, 24, 237–254. [Google Scholar] [PubMed]
- Da Cruz Perez, D.E.; De Abreu Alves, F.; Nishimoto, I.N.; De Almeida, O.P.; Kowalski, L.P. Prognostic Factors in Head and Neck Adenoid Cystic Carcinoma. Oral Oncol. 2006, 42, 139–146. [Google Scholar] [CrossRef] [PubMed]
- Grabenstetter, A.; Brogi, E.; Zhang, H.; Razavi, P.; Reis-Filho, J.S.; VanZee, K.J.; Norton, L.; Wen, H.Y. Solid-Basaloid Variant of Adenoid Cystic Carcinoma of the Breast with near Complete Response to Neoadjuvant Chemotherapy. NPJ Breast Cancer 2022, 8, 93. [Google Scholar] [CrossRef]
- Yang, L.; Wang, C.; Liu, M.; Wang, S. Evaluation of Adjuvant Treatments for Adenoid Cystic Carcinoma of the Breast: A Population-Based, Propensity Score Matched Cohort Study from the SEER Database. Diagnostics 2022, 12, 1760. [Google Scholar] [CrossRef] [PubMed]
- Marinello, J.; Delcuratolo, M.; Capranico, G. Anthracyclines as Topoisomerase II Poisons: From Early Studies to New Perspectives. Int. J. Mol. Sci. 2018, 19, 3480. [Google Scholar] [CrossRef]
- Vranic, S.; Frkovic-Grazio, S.; Lamovec, J.; Serdarevic, F.; Gurjeva, O.; Palazzo, J.; Bilalovic, N.; Lee, L.M.J.; Gatalica, Z. Adenoid Cystic Carcinomas of the Breast Have Low Topo IIα Expression but Frequently Overexpress EGFR Protein without EGFR Gene Amplification. Hum. Pathol. 2010, 41, 1617–1623. [Google Scholar] [CrossRef] [PubMed]
- Glover, T.E.; Butel, R.; Bhuller, C.M.; Senior, E.L. An Unusual Presentation of Adenoid Cystic Carcinoma of the Breast with Metastatic Disease in the Clavicle. BJR Case Rep. 2017, 3, 20160119. [Google Scholar] [CrossRef]
- Monga, V.; Leone, J.P. Metastatic Adenoid Cystic Carcinoma of the Breast. Breast J. 2016, 22, 239–240. [Google Scholar] [CrossRef]
- Mhamdi, H.A.; Kourie, H.R.; Jungels, C.; Aftimos, P.; Belbaraka, R.; Piccart-Gebhart, M. Adenoid Cystic Carcinoma of the Breast—An Aggressive Presentation with Pulmonary, Kidney, and Brain Metastases: A Case Report. J. Med. Case Rep. 2017, 11, 303. [Google Scholar] [CrossRef] [PubMed]
- Herzberg, A.J.; Bossen, E.H.; Walther, P.J. Adenoid Cystic Carcinoma of the Breast Metastatic to the Kidney. A Clinically Symptomatic Lesion Requiring Surgical Management. Cancer 1991, 68, 1015–1020. [Google Scholar] [CrossRef]
- Sołek, J.M.; Braun, M.; Kalwas, M.; Jesionek-Kupnicka, D.; Romańska, H.M. Adenoid Cystic Carcinoma of the Breast—An Uncommon Malignancy with Unpredictable Clinical Behaviour. A Case Series of Three Patients. Contemp. Oncol. (Pozn) 2020, 24, 263–265. [Google Scholar] [CrossRef]
- Hassoun, H.; Alabed, Y.Z.; Karls, S.; Probst, S.; Laufer, J. 18F-FDG PET/CT Imaging of Bilateral Renal Metastasis of Breast Adenoid Cystic Carcinoma. Clin. Nucl. Med. 2016, 41, 148–149. [Google Scholar] [CrossRef]
- Vranić, S.; Bilalović, N.; Lee, L.M.J.; Kruslin, B.; Lillenberg, S.L.; Gatalica, Z. PIK3CA and PTEN Mutations in Adenoid Cystic Carcinoma of the Breast Metastatic to Kidney. Hum. Pathol. 2007, 38, 1425–1431. [Google Scholar] [CrossRef]
- Nozoe, T.; Nozoe, E.; Ohga, T.; Ezaki, T.; Sueishi, K. A Case of Adenoid Cystic Carcinoma of the Breast. J. Med. Investig. 2018, 65, 289–291. [Google Scholar] [CrossRef]
- Silva, I.; Tome, V.; Oliveira, J. Adenoid Cystic Carcinoma of the Breast with Cerebral Metastisation: A Clinical Novelty. BMJ Case. Rep. 2011, 2011, bcr0820114692. [Google Scholar] [CrossRef] [PubMed]
- Kim, M.; Lee, D.; Im, J.; Suh, K.J.; Keam, B.; Moon, H.; Im, S.; Han, W.; Park, I.A.; Noh, D. Adenoid Cystic Carcinoma of the Breast: A Case Series of Six Patients and Literature Review. Cancer Res. Treat. 2014, 46, 93–97. [Google Scholar] [CrossRef] [PubMed]
- Koller, M.; Ram, Z.; Findler, G.; Lipshitz, M. Brain Metastasis: A Rare Manifestation of Adenoid Cystic Carcinoma of the Breast. Surg. Neurol. 1986, 26, 470–472. [Google Scholar] [CrossRef]
- Gillie, B.; Kmeid, M.; Asarian, A.; Xiao, P. Adenoid Cystic Carcinoma of the Breast with Distant Metastasis to the Liver and Spleen: A Case Report. J. Sur. Case Rep. 2020, 2020, rjaa483. [Google Scholar] [CrossRef]
- Vasudevan, G.; John, A.M.; Vijaykumar, D.K.; Vallonthaiel, A.G. Adenoid Cystic Carcinoma of the Breast with Late Recurrence and High-Grade Transformation. BMJ. Case Rep. 2023, 16, e252336. [Google Scholar] [CrossRef] [PubMed]
- Lei, T.; Shi, Y.; Da, W.; Xia, C.; Wang, H. A Novel EWSR1-MYB Fusion in an Aggressive Advanced Breast Adenoid Cystic Carcinoma with Mixed Classical and Solid-Basaloid Components. Virchows Arch. 2023. [Google Scholar] [CrossRef]
- Li, L.; Zhang, D.; Ma, F. Adenoid Cystic Carcinoma of the Breast May Be Exempt from Adjuvant Chemotherapy. J. Clin. Med. 2022, 11, 4477. [Google Scholar] [CrossRef] [PubMed]
- Bardia, A.; Hurvitz, S.A.; Tolaney, S.M.; Loirat, D.; Punie, K.; Oliveira, M.; Brufsky, A.; Sardesai, S.D.; Kalinsky, K.; Zelnak, A.B.; et al. Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. N. Engl. J. Med. 2021, 384, 1529–1541. [Google Scholar] [CrossRef] [PubMed]
- Wolber, P.; Nachtsheim, L.; Hoffmann, F.; Klußmann, J.P.; Meyer, M.; von Eggeling, F.; Guntinas-Lichius, O.; Quaas, A.; Arolt, C. Trophoblast Cell Surface Antigen 2 (Trop-2) Protein Is Highly Expressed in Salivary Gland Carcinomas and Represents a Potential Therapeutic Target. Head Neck Pathol. 2021, 15, 1147–1155. [Google Scholar] [CrossRef]
- Lee, R.H.; Wai, K.C.; Chan, J.W.; Ha, P.K.; Kang, H. Approaches to the Management of Metastatic Adenoid Cystic Carcinoma. Cancers 2022, 14, 5698. [Google Scholar] [CrossRef]
- Ho, A.S.; Ochoa, A.; Jayakumaran, G.; Zehir, A.; Mayor, C.V.; Tepe, J.; Makarov, V.; Dalin, M.G.; He, J.; Bailey, M.; et al. Genetic Hallmarks of Recurrent/Metastatic Adenoid Cystic Carcinoma. J. Clin. Investig. 2019, 129, 4276–4289. [Google Scholar] [CrossRef] [PubMed]
- Ferrarotto, R.; Mitani, Y.; Diao, L.; Guijarro, I.; Wang, J.; Zweidler-McKay, P.; Bell, D.; William, W.N., Jr.; Glisson, B.S.; Wick, M.J.; et al. Activating NOTCH1 Mutations Define a Distinct Subgroup of Patients with Adenoid Cystic Carcinoma Who Have Poor Prognosis, Propensity to Bone and Liver Metastasis, and Potential Responsiveness to Notch1 Inhibitors. J. Clin. Oncol. 2017, 35, 352–360. [Google Scholar] [CrossRef]
- Frierson, H.F.; Moskaluk, C.A. Mutation Signature of Adenoid Cystic Carcinoma: Evidence for Transcriptional and Epigenetic Reprogramming. J. Clin. Investig. 2013, 123, 2783–2785. [Google Scholar] [CrossRef]
- Brayer, K.J.; Kang, H.; El-Naggar, A.K.; Andreasen, S.; Homøe, P.; Kiss, K.; Mikkelsen, L.; Heegaard, S.; Pelaez, D.; Moeyersoms, A.; et al. Dominant Gene Expression Profiles Define Adenoid Cystic Carcinoma (ACC) from Different Tissues: Validation of a Gene Signature Classifier for Poor Survival in Salivary Gland ACC. Cancers 2023, 15, 1390. [Google Scholar] [CrossRef]
BREAST ACC | KIDNEY METASTASIS | |
---|---|---|
CYTOKERATINS | + | + |
CK5/6 | + | + |
CK7 | + | ND |
CK18 | ND | − |
CK19 | + | + |
CK20 | ND | − |
CD7 | +/− | ND |
CD10 | − | − |
VIMENTIN | + | + |
CD117 | +/− | +/− |
PAX-8 | − | − |
PR | − | ND |
ER | − | ND |
CD10 | − | − |
S100 | − | ND |
GATA-3 | − | − |
ABPAS | ND | + |
AMACAR | ND | − |
SMA | + | −/+ |
CEA | ND | − |
CALPONIN | ND | − |
P53 | ND | − |
P63 | + | ND |
Article | Age | Stage | Primary Treatment | DFS | Cancer Dissemination | Secondary Treatment | Treatment Response |
---|---|---|---|---|---|---|---|
Glover et al., 2016 [19] | 50 | T1N0M0 | Mastectomy | 13 yrs | Bones (clavicle) | metastasectomy, adjuvant RTH | - |
Monga et al., 2016 [20] | 57 | - | Lumpectomy + RTH | 8 yrs | Lung (isolated) Multiple after 3 yrs: scalp lesion, bones (rib, vertebrae, femur, pelvis) | Lobectomy next 3 years removal of skin lesion, palliative RTH (spine lesion), CTH (PXL) | OS 2 yrs |
Mhamdi et al., 2017 [21] | 65 | T3N0M0 | Mastectomy with lymphadenectomy + RTH | 4 yrs | Lungs, kidney, brain, pancreas | Metastasectomy, RTH | - |
Herzberg et al., 1991 [22] | 57 | T1cN0M0 | Mastectomy | 6 yrs | Lung After 12 yrs kidney | Metastasectomy | CR (2 yrs of follow-up after surgery) |
Sołek et al., 2020 [23] | 41 | T1N0Mx | Lumpectomy + RTH | 23 mo(s) | Brain, lungs, liver | CTH (4 AC cycles), metastasectomy (lungs), RTH and CTH (AC, DXL, capecitabine, and cisplatin in monotherapy) | SD |
Sołek et al., 2020 [23] | 52 | T2N0Mx | Mastectomy + RTH | 1 mo | Lungs | 4 different CTH (no details) | SD |
Hassoun et al., 2016 [24] | 40 | - | Mastectomy | 15 yrs | Lungs After 10 yrs kidney | Right upper lobectomy | - |
Vranic et al., 2007 [25] | 71 | T1cN0M0 | Mastectomy | 5 yrs | Kidney | Radical nephrectomy | CR (OS 12 yrs, death not related to cancer) |
Nozoe et al., 2018 [26] | 85 | T3N0M1 (lungs) | Mastectomy, refused CTH | - | - | - | - |
Silva et al., 2011 [27] | 37 | T2N1M0 | Mastectomy + adjuvant CTH (6 AC cycles) + RTH | 2 yrs | Lungs, liver, after a yr cerebellum, brainstem, bones | CTH (6 DXL + NVB (6 cycles), after a yr CTH (5-FU) | OS 3 yrs |
Kim et al., 2014 [28] | 33 | T2N0M0 | Lumpectomy + RT + adjuvant CTH (FAC) | 28 mo(s) | Lungs after 17 months recurrence in lungs | Metastasectomy, palliative CTH (6 DXL cycles + 3 capecitabine cycles after recurrence) | SD (1 yr follow-up) |
Kim et al., 2014 [29] | 58 | T2N0M0 | Mastectomy with lymphadenectomy + adjuvant CTH (6 CAP cycles) | 6 yrs | Lungs, bone (scapula), and liver | Palliative RTH (scapula) | PD (1 mo) |
Koller et al., 1986 [30] | 49 | T?N0 | Mastectomy | 12 yrs | Lungs, brain | Metastasectomy | CR (lost to follow-up after 5 yrs) |
Gillie et al., 2020 [31] | 67 | T2N0M0 | Mastectomy with lymphadenectomy | 1 yr | Liver, spleen | Best supportive care | - |
Vasudevan et al., 2023 [32] | 48 | T1N0M0 | R1 lumpectomy followed by mastectomy with lymphadenectomy + tamoxifen (5 yrs) | 11 yrs | Left chest (2 lesions), After 1 yr local recurrence and progression in lungs | Metastasectomy + RTH (refused CTH) | _ |
Lei et al., 2023 [33] | 70 | T4N1M0 | Mastectomy + lymphadenectomy + CTH (2 AC cycles)) | 1 mo | Rib, lungs | palliative CTH (10 non-specified cycles) | OS 1 yr |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Rypel, J.; Kubacka, P.; Mykała-Cieśla, J.; Pająk, J.; Bulska-Będkowska, W.; Chudek, J. Locally Advanced Adenoid Cystic Carcinoma of the Breast—A Case Report with a Review of the Literature. Medicina 2023, 59, 2005. https://doi.org/10.3390/medicina59112005
Rypel J, Kubacka P, Mykała-Cieśla J, Pająk J, Bulska-Będkowska W, Chudek J. Locally Advanced Adenoid Cystic Carcinoma of the Breast—A Case Report with a Review of the Literature. Medicina. 2023; 59(11):2005. https://doi.org/10.3390/medicina59112005
Chicago/Turabian StyleRypel, Joanna, Paulina Kubacka, Joanna Mykała-Cieśla, Jacek Pająk, Weronika Bulska-Będkowska, and Jerzy Chudek. 2023. "Locally Advanced Adenoid Cystic Carcinoma of the Breast—A Case Report with a Review of the Literature" Medicina 59, no. 11: 2005. https://doi.org/10.3390/medicina59112005